CHRN
ChronoScale Corporation
There isn't enough reported data to score CHRN yet.
INTC
Intel Corporation
INTC lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
CHRN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CHRN's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
INTC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Healthy | |
| Healthy |
INTC's revenue, cash flow and balance sheet are currently healthy, but its profitability is under pressure.
CHRN PE Valuation
CHRN has no meaningful PE right now: it lost money over the past year.
INTC PE Valuation
INTC has no meaningful PE right now: it lost money over the past year.
CHRN Forward outlook
There aren't enough analyst estimates for CHRN to show an outlook.
INTC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Broad | |
| Low |
Analysts expect earnings and revenue growth for INTC, with profitability improving. However, they disagree widely on these estimates.
CHRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2026 | -$6.83 | +$0.40 |
| Q4 2025 | -$6.59 | +$1.84 |
| Q3 2025 | -$5.56 | +$4.19 |
| Q2 2025 | -$6.52 | +$5.33 |
| Q1 2025 | -$7.23 | +$7.32 |
| Q4 2024 | -$8.43 | +$8.07 |
| Q3 2024 | -$9.75 | +$7.05 |
| Q2 2024 | -$11.85 | +$6.30 |
CHRN has the stronger earnings trend. Trailing diluted EPS is down 194% for CHRN versus INTC down 24,000%.
INTC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.41 | — |
| Q3 2026 | -$2.39 | -24000% |
| Q2 2026 | -$2.09 | +$2.68 |
| Q1 2026 | -$0.60 | +$3.88 |
| Q4 2025 | -$0.06 | +$4.32 |
| Q3 2025 | $0.01 | +$3.72 |
| Q2 2025 | -$4.77 | -2088% |
| Q1 2025 | -$4.48 | -562% |
| Q4 2024 | -$4.38 | -1195% |
INTC has swung to a loss: it lost $2.39 per share over the past year, after a profit the year before.
CHRN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $41.5M | +881% |
| Q1 2026 | $2.1M | -37% |
| Q4 2025 | $3.1M | -38% |
| Q3 2025 | $4.2M | +2.4% |
| Q2 2025 | $2.1M | -58% |
| Q1 2025 | $3.4M | -10% |
| Q4 2024 | $5.1M | +5% |
| Q3 2024 | $4.1M | -10% |
CHRN's revenue is growing: $41M last quarter, up 1917% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -60% | +133 points |
| Q1 2026 | -262% | -161 points |
| Q4 2025 | -144% | -100 points |
| Q3 2025 | -33% | +31 points |
| Q2 2025 | -193% | -146 points |
| Q1 2025 | -102% | -15 points |
| Q4 2024 | -44% | +27 points |
| Q3 2024 | -64% | -0.3 points |
CHRN's operating margin was −60% last quarter, up 133 points from the same quarter a year ago.
INTC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $16.5B | +21% |
| Q2 2026 | $16.1B | +25% |
| Q1 2026 | $13.6B | +7.2% |
| Q4 2025 | $13.7B | -4.1% |
| Q3 2025 | $13.7B | +2.8% |
| Q2 2025 | $12.9B | +0.2% |
| Q1 2025 | $12.7B | -0.4% |
| Q4 2024 | $14.3B | -7.4% |
INTC has the edge over CHRN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | +10 points |
| Q2 2026 | 11% | +36 points |
| Q1 2026 | -23% | -21 points |
| Q4 2025 | 4.2% | +1.4 points |
| Q3 2025 | 5% | +73 points |
| Q2 2025 | -25% | -9.4 points |
| Q1 2025 | -2.4% | +6 points |
| Q4 2024 | 2.9% | -14 points |
INTC has the edge over CHRN on profitability, with a higher operating margin.
CHRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $11.6M | +$13.6M |
| Q1 2026 | -$2.1M | -$148K |
| Q4 2025 | -$4.5M | -$3M |
| Q3 2025 | -$2.1M | +$212K |
| Q2 2025 | -$3.5M | -$814K |
| Q1 2025 | -$2M | +$1.5M |
| Q4 2024 | -$1.5M | +$173K |
| Q3 2024 | -$2.3M | +$1.1M |
CHRN's free cash flow has turned positive after six years mostly in the red: $3M over the past year.
INTC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +774% |
| Q2 2026 | $4.5B | +$6B |
| Q1 2026 | -$2.5B | +$1.8B |
| Q4 2025 | $800M | +$3.5B |
| Q3 2025 | $121M | +$2.5B |
| Q2 2025 | -$1.5B | +$1.9B |
| Q1 2025 | -$4.4B | +$2.8B |
| Q4 2024 | -$2.7B | -$597M |
INTC has the edge over CHRN on cash flow, with more consistent year-over-year improvement.
CHRN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3981% | +142M shares |
| 1 year | +8489% | +144M shares |
| 3 years | +16727% | +145M shares |
| 5 years | +34737% | +145M shares |
CHRN has 145M diluted shares, up 8489% from a year ago.
INTC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4% | +203M shares |
| 1 year | +17% | +776M shares |
| 3 years | +25% | +1.1B shares |
| 5 years | +30% | +1.2B shares |
| Available history | +19% | +834M shares |
INTC has the edge over CHRN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | $114M |
| Q1 2021 | $2.3B |
CHRN Net Leverage
CHRN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
INTC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.0x | Healthy |
| Q2 2026 | 3.1x | Elevated |
| Q1 2026 | 3.9x | Elevated |
| Q4 2025 | 3.4x | Elevated |
| Q3 2025 | 4.0x | Elevated |
| Q1 2025 | 69.6x | High |
| Q3 2024 | 23.8x | High |
| Q2 2024 | 4.3x | High |
INTC's net debt is about 2.0 years of its operating earnings (EBITDA), down from 4.0 years a year ago.
CHRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.3 | Neutral |
| Stochastic | 8.3 | Oversold |
CHRN's weekly RSI is 37 (neutral) and its Stochastic is 8 (oversold).
INTC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.1 | Neutral |
| Stochastic | 7.7 | Oversold |
INTC's weekly RSI is 38 (neutral) and its Stochastic is 8 (oversold).
CHRN PE vs Technology Sector
CHRN has no meaningful PE right now: it lost money over the past year.
INTC PE vs Technology Sector
| Metric | INTC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
INTC has no meaningful PE right now: it lost money over the past year.
CHRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.4 | 30% below |
| 20 week MA | $18.8 | 42% below |
| 50 week MA | $14.5 | 25% below |
| 100 week MA | $10.1 | 7.5% above |
| 200 week MA | $14.9 | 27% below |
CHRN's trend is mixed: it's above one of its five weekly moving averages, and 27% below its 200-week average.
INTC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $88.4 | 31% below |
| 20 week MA | $95.3 | 36% below |
| 50 week MA | $79.3 | 23% below |
| 100 week MA | $52.1 | 18% above |
| 200 week MA | $42.5 | 44% above |
INTC has the edge over CHRN on trend strength, trading above more of its moving averages.
CHRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $78.8 | $104.7 | +33% |
| 2021 | $104.7 | $45.3 | -57% |
| 2022 | $45.3 | $18.6 | -59% |
| 2023 | $18.6 | $37.5 | +102% |
| 2024 | $37.5 | $9.74 | -74% |
| 2025 | $9.74 | $5.56 | -43% |
| 2026 YTD | $5.56 | $10.9 | +95% |
CHRN has the edge over INTC on returns for 2026, with the stronger performance.
INTC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $60.1 | $47.1 | -22% |
| 2021 | $47.1 | $51.3 | +9% |
| 2022 | $51.3 | $26.1 | -49% |
| 2023 | $26.1 | $50.3 | +93% |
| 2024 | $50.3 | $20.3 | -60% |
| 2025 | $20.3 | $36.2 | +78% |
| 2026 YTD | $36.2 | $61.2 | +69% |
INTC is up 69% so far in 2026, after finishing lower in three of the previous six years.